Completed
Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies.
NCT02947165
- Conditions
- Breast Cancer, Breast Diseases, Breast Neoplasms, +38 more
- Locations
-
- Sarah Cannon Research Institute SC Nashville, Tennessee, United States
- Huntsman Cancer Institute SC Salt Lake City, Utah, United States
- Novartis Investigative Site Salzburg, Austria
- Novartis Investigative Site Toronto, Ontario, Canada